from the swiftly evolving industry of oncology investigation, correct and effective mutation screening is very important for creating qualified therapies. The KRAS solutions System plays a pivotal purpose With this landscape by presenting thorough methods for KRAS mutation profiling and analysis. KRAS mutations, located in about 95% of RAS-similar